Om Research LLC

1. Boehringer Ingelheim International GmbH $508,096 267 payments
2. AbbVie, Inc. $452,229 102 payments
3. Genentech, Inc. $449,984 106 payments
4. Eli Lilly and Company $420,599 39 payments
5. Janssen Research & Development, LLC $403,547 82 payments
6. Allergan Inc. $370,974 68 payments
7. Takeda Pharmaceuticals U.S.A., Inc. $349,482 156 payments
8. Sanofi US Services Inc. $310,352 50 payments
9. Pfizer Inc. $289,047 125 payments
10. Otsuka Pharmaceutical Development & Commercialization, Inc. $240,631 10 payments

1. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $479,253 225 payments
2. Roche Cancer Screening Collection Study $382,209 71 payments
3. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $258,582 53 payments
4. A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $243,946 37 payments
5. A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet $241,321 102 payments
6. A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis $183,961 56 payments
7. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $172,557 37 payments
8. A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $143,174 24 payments
9. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $138,258 3 payments
10. A Multicenter Randomized Doubleblind Parallelgroup Study to Assess the Efficacy and Safety of Oral Etrasimod As Induction and Maintenance Therapy for Moderately to Severely Active Crohns Disease $128,147 82 payments

1. Patient care $115,183 59 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.